Understanding and treating genetic changes in metastatic breast cancer
Diagnosis and Treatment of APOBEC Mutagenesis in Metastatic Breast Cancer
This study is looking at how certain genetic changes in metastatic breast cancer, especially those caused by the APOBEC enzyme, might make the cancer harder to treat, and it’s for patients who want to learn more about their cancer and how to get the best treatment.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Sloan-Kettering Inst Can Research NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project ID | NIH-10902114 on NIH RePORTER |
What this research studies
This research investigates the role of specific genetic mutations, particularly those caused by the APOBEC enzyme, in metastatic breast cancer. By analyzing the differences between primary and metastatic tumors, the study aims to identify how these mutations contribute to resistance against standard treatments. Patients may undergo genomic analyses to help determine the presence of these mutations, which could inform more effective treatment strategies tailored to their specific cancer profile.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with metastatic estrogen receptor-positive breast cancer who have shown resistance to standard endocrine therapies.
Not a fit: Patients with early-stage breast cancer or those whose cancer is not estrogen receptor-positive may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for patients with metastatic breast cancer, improving survival rates and quality of life.
How similar studies have performed: Previous research has shown promising results in understanding mutational signatures in cancer, suggesting that this approach could yield valuable insights and advancements in treatment.
Where this research is happening
New York, United States
- Sloan-Kettering Inst Can Research — New York, United States (Active)
Researchers
- Principal investigator: Chandarlapaty, Sarat — Sloan-Kettering Inst Can Research
- Study coordinator: Chandarlapaty, Sarat
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.